13 December 2018

Researchers of Radboudumc have discovered that the iron in metal surgical implants can activate drugs such as antibiotics, thus enabling targeted therapy. With this method, antibiotics in the blood can target infections in the vicinity of an implant, write researchers Marja Bulte-ter Meer and Leo Schultze Kool in Chemical Communications.

Metal implants are widely used in medical care, from artificial heart valves to trauma surgery and from dental prostheses to orthopedic surgery. However, the introduction of artificial tissue in the body entails a high risk of bacterial infection. As a result, patients with an implant often are required to use preventative antibiotics for long periods. This does not always have the desired effect, and can even be harmful, because these antibiotics are active throughout the body.
Enzyme-prodrug therapy
It is therefore more effective if drugs are active only in the vicinity of the implant, for example by administering the drug locally. One method to achieve this is known as enzyme-prodrug therapy (EPT). Patients receive inactive drugs – prodrugs – which can be converted into active drugs in the body. But for this work, the implant has to contain the enzymes needed for this conversion.
Discovered by accident
Marja Bulte-ter Meer, a PhD candidate working with Professor of Interventional Radiology Leo Schultze Kool of Radboudumc, discovered by accident that a certain type of widely used metal implant has an enzyme-like effect. This enables the implants to cleave sugar groups from molecules. This mechanism can be used for drug treatment by adding a sugar group to a drug, which results in a prodrug. As soon as the sugar group is cleaved from the molecule, the drug becomes active.
The researchers made their discovery when working with implants consisting of an alloy of cobalt, nickel, chromium and molybdenum. The implants themselves were inert, but a version with small grooves in the metal had strong activity in cleaving sugar groups. On closer inspection it appeared that iron had been deposited in these grooves. This iron turned out to be responsible for the efficient conversion of the drugs to their active form. The underlying mechanism for this process is not yet known.

Pure iron
Implants of pure iron would work best with enzyme-prodrug therapy. However, pure iron is chemically instable and cannot be used to make implants. The researchers therefore thought it would be a better idea to provide existing implants with an iron coating. Laboratory tests have shown that various implant materials with an iron coating can effectively convert an antibiotic pro-drug to an active drug.
During the past 18 months, Bulte-ter Meer and Schulze Kool have developed their discovery in collaboration with Aarhus University (Denmark) and implant manufacturer Fort Wayne Medical. The researchers have now applied for a patent on the enzymatic function of metallic implants. As a result, this technique can be used extensively for a wide range of drugs.

Marja Bulte - ter Meer is member of theme Rare cancers.
Leo Schultze Kool is member of theme Vascular damage.

Related news items

Four Veni grants for young RIMLS researchers

22 July 2019

Four young researchers, affiliated to the RIMLS, have each received a Veni grant of 250,000 Euro from NWO. Our researchers received this prestigious grant for their remarkable and original talent and their ability to carry out innovative research.

read more

Bas Loomans received Mid-Career Award

18 July 2019

Bas Loomans received in Vancouver the STEPHEN BAYNE MID-CAREER AWARD of the International Association for Dental Research (IADR)

read more

4,8 million euros for prevention of tuberculosis among people with diabetes in Africa

16 July 2019

Reinout van Crevel and Lindsey te Brake have received European funding of 4.8 million euros to lead an international consortium to screen thousands of people with diabetes in Uganda and Tanzania for TB, and investigate the effect and costs of 3 months preventive treatment for TB.

read more

50.000 grant for Paul de Jonge and Harry Dolstra

15 July 2019

Paul de Jonge and Harry Dolstra, theme Cancer development and immune defense, received a €50.000,- (NWA-IDG) grant for their project regarding cancer immunotherapy.

read more

Handbook of biomarkers and precision medicine a new publication by Alain van Gool

12 July 2019

Alain van Gool published a new handbook on biomarkers and applications in (pre)clinical drug development for precision medicine.

read more

The real impact of menstrual complaints on work and school productivity

8 July 2019

Menstrual period symptoms may be linked to nearly nine days of lost productivity every year, through presenteeism, suggests the largest study of its kind, published in the journal BMJ Open. But the real impact on women and society is underestimated and poorly appreciated, say the researchers.

read more